Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2369369 | 0.98 | — | — | |
| SCHEMBL4865787 | 0.65 | — | — | |
| SCHEMBL10414835 | 0.62 | — | — | |
| SCHEMBL14000288 | 0.59 | — | — | |
| SCHEMBL1402798 | 0.59 | — | — | |
| SCHEMBL8313692 | 0.59 | KMT2A (0.36) | TMEM97SIGMAR1 | |
| SCHEMBL7668456 | 0.59 | — | — | |
| SCHEMBL13650783 | 0.55 | — | — | |
| SCHEMBL20680547 | 0.55 | — | — | |
| SCHEMBL11033412 | 0.53 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011107867-A2 | COMPOUND AND COMPOSITION AND THEIR USE IN THE TREATMENT OF DISEASES RELATED TO COPPER RETENTION | KANDULA MAHESH (IN) | 2011-09-09 | — | — | WO | claimed |
| US-20110218236-A1 | COMPOUND AND COMPOSITION AND THEIR USES THEREOF | KRISHANI BIOSCIENCES (P) LTD (IN) | 2011-09-08 | — | — | US | claimed |
| WO-2011107867-A2 | COMPOUND AND COMPOSITION AND THEIR USE IN THE TREATMENT OF DISEASES RELATED TO COPPER RETENTION | KANDULA MAHESH (IN) | 2011-09-09 | — | — | WO | disclosed |
| US-20110218238-A1 | COMPOUNDS, COMPOSITIONS, FORMULATIONS AND THEIR USES THEREOF | KRISHANI BIOSCIENCES (P) LTD (IN) | 2011-09-08 | — | — | US | disclosed |
| US-20110218236-A1 | COMPOUND AND COMPOSITION AND THEIR USES THEREOF | KRISHANI BIOSCIENCES (P) LTD (IN) | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218236-A1 | COMPOUND AND COMPOSITION AND THEIR USES THEREOF | SLC26A4, SLC26A3, SLC10A1 | TMEM97 1848/4885SIGMAR1 1726/4885 |
| US-20110218238-A1 | COMPOUNDS, COMPOSITIONS, FORMULATIONS AND THEIR USES THEREOF | SLC10A1, ABCB11, NPC1L1 | TMEM97 560/4885SIGMAR1 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.